GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuCell Corp (NAS:ICCC) » Definitions » Total Inventories

ICCC (ImmuCell) Total Inventories : $7.46 Mil (As of Sep. 2024)


View and export this data going back to 1995. Start your Free Trial

What is ImmuCell Total Inventories?

ImmuCell's total inventories for the quarter that ended in Sep. 2024 was $7.46 Mil. ImmuCell's average total inventories from the quarter that ended in Jun. 2024 to the quarter that ended in Sep. 2024 was $7.38 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. ImmuCell's Net-Net Working Capital per share for the quarter that ended in Sep. 2024 was $-0.99.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. ImmuCell's Days Inventory for the three months ended in Sep. 2024 was 152.08.

Inventory Turnover measures how fast the company turns over its inventory within a year. ImmuCell's Inventory Turnover for the quarter that ended in Sep. 2024 was 0.60.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. ImmuCell's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 1.23.


ImmuCell Total Inventories Historical Data

The historical data trend for ImmuCell's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuCell Total Inventories Chart

ImmuCell Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.52 2.09 3.09 6.04 7.81

ImmuCell Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.39 7.81 7.15 7.30 7.46

ImmuCell Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


ImmuCell  (NAS:ICCC) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

ImmuCell's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2024 is

Net-Net Working Capital Per Share (Q: Sep. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(3.809+0.75 * 2.308+0.5 * 7.46-18.037
-0-0)/8.8331
=-0.99

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

ImmuCell's Days Inventory for the three months ended in Sep. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Sep. 2024 )/Cost of Goods Sold (Q: Sep. 2024 )*Days in Period
=7.38/4.428*365 / 4
=152.08

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

ImmuCell's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Sep. 2024 ) / Average Total Inventories (Q: Sep. 2024 )
=4.428 / 7.38
=0.60

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

ImmuCell's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=7.38 / 6.012
=1.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


ImmuCell Total Inventories Related Terms

Thank you for viewing the detailed overview of ImmuCell's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmuCell Business Description

Traded in Other Exchanges
Address
56 Evergreen Drive, Portland, ME, USA, 04103
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
Executives
Bryan K. Gathagan director 56 EVERGREEN DRIVE, PORTLAND ME 04103
David Cunningham director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Gloria F Basse director 56 EVERGREEN DRIVE, PORTLAND ME 04103
David Scott Tomsche director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Steven T. Rosgen director C/O IMMUCELL CORPORATION, 56 EVERGREEN DR., PORTLAND ME 04103
Norman H Pessin other: See Explanation of Responses C/O LEVY, HARKINS & CO., INC., 366 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10017
Brian L. Pessin other: See Explanation of Responses 310 EAST 75TH STREET, APT. 2A, NEW YORK NY 10021
Joseph H Crabb director, officer: Vice President and CSO IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Elizabeth Luttrell Williams officer: Vice Pres. of Mfg Operations C/O IMMUCELL CORPORATION, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Jonathan E Rothschild director, 10 percent owner C/O IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Linda Rhodes director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Paul R Wainman director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Michael F Brigham director, officer: President and CEO IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Bobbi Jo Kunde other: Director of Sales and Marketin 56 EVERGREEN DRIVE, PORTLAND ME 04103
Robert C Bruce director 56 EVERGREEN DRIVE, PORTLAND ME 04103